West Pharmaceutical Services in the news

West Pharmaceutical Services Inc. stock rose 2.17% to $344.25, outperforming the market and breaking a three-day losing streak.

West Pharmaceutical's President and CEO, Michel Lagarde, disclosed an initial ownership of 7,850 shares of the company's common stock.

West Pharmaceutical Services' Sr. VP & Chief HR Officer sold over $2.7 million in company shares.

West Pharmaceutical Services has strong market momentum, but its valuation is now closely aligned with its intrinsic value based on cash flow, requiring sustained growth to justify current prices.

West Pharmaceutical Services shows strong financial health and positive analyst sentiment, with a potential 19% stock upside in the healthcare sector.

Generation Investment Management's Q2 2026 letter praises West Pharmaceutical Services for its indispensable, market-leading solutions in injectable drug delivery, citing its critical role in patient safety and high market share in key drug segments.

West Pharmaceutical Services stock is considered undervalued at $339.97 compared to a $404 fair value, driven by GLP-1 growth and future operational efficiencies.

West Pharmaceutical Services Inc. will present at two investor conferences in September to discuss its operations as a global injectable drug-delivery supplier.

West Pharmaceutical Services stock holds steady with a moderate buy rating and analyst target price above its current trading level.

West Pharmaceutical Services Inc. stock gained on Wednesday but still underperformed its competitors.

West Pharmaceutical Services is facing renewed valuation scrutiny after a period of strong share price performance, despite its specialized role in pharmaceutical packaging and drug delivery.

West Pharmaceutical Services (WST) shows mixed valuation signals, with analysts considering it undervalued at $338.65 against a fair value of $404, while another metric suggests it is expensive.

West Pharmaceutical Services shows a promising 19.93% upside potential for investors, supported by strong financial metrics, positive analyst sentiment, and a robust market position in injectable drug systems.

West Pharmaceutical Services Inc. stock saw a strong trading day, outperforming competitors.

West Pharmaceutical Services saw PDT Partners acquire a new stake following strong Q2 earnings and revenue growth, alongside positive analyst sentiment and guidance.

West Pharmaceutical Services shows strong financial performance and positive analyst sentiment due to high demand for its injectable solutions, especially for GLP-1 drugs.

West Pharmaceutical Services stock recently reached a 52-week high after a 27% increase over the past month, outperforming its sector and industry.

Cibc World Market Inc. recently purchased 16,794 shares of West Pharmaceutical Services, a medical instruments supplier, for approximately $6.03 million, amidst other institutional investments and positive analyst ratings.

West Pharmaceutical Services stock has outperformed the market and its sector due to strong demand for injectable solutions, particularly for GLP-1 drugs, leading to significant sales growth and positive analyst projections.

West Pharmaceutical Services will present at two major healthcare conferences in September 2026 to discuss its injectable drug solutions and market position.